Maven Securities’s Amylyx Pharmaceuticals AMLX Stock Holding History

Maven Securities’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Sell	25,000 -25,000	-50%	-$387K	0.01%	306
2026 Q1	$695K	Buy	+50,000	New	+$703K	0.01%	351
2025 Q4	–	Sell	-70,000	Closed	-$951K	–	458
2025 Q3	$951K	Buy	+70,000	New	+$659K	0.02%	372
2024 Q3	–	Sell	-100,000	Closed	-$190K	–	866
2024 Q2	$190K	Buy	100,000 +75,000	+300%	+$145K	﹤0.01%	890
2024 Q1	$71K	Buy	+25,000	New	+$327K	﹤0.01%	332
2023 Q2	–	Sell	-100,000	Closed	-$2.93M	–	857
2023 Q1	$2.93M	Sell	100,000 -50,000	-33%	-$1.74M	0.06%	219
2022 Q4	$5.54M	Buy	+150,000	New	+$5.32M	0.13%	88

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Maven Securities's AMLX Position: Q2 2026 in Review

Maven Securities reduced its Amylyx Pharmaceuticals (AMLX) stake by 50% in Q2 2026, selling an estimated $387K and leaving 25,000 shares worth $449K. The position accounts for 0.01% of the portfolio, ranked #306.

Maven Securities first reported a position in AMLX in Q4 2022 and has held it in 7 quarters since. The position peaked at $5.54M in Q4 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Maven Securities held 25,000 shares of Amylyx Pharmaceuticals worth $449K as of Q2 2026.
Maven Securities sold 25,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $387K.
Amylyx Pharmaceuticals made up 0.01% of Maven Securities's portfolio in Q2 2026, its #306 holding.
Maven Securities first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
Maven Securities's Amylyx Pharmaceuticals position peaked at $5.54M in Q4 2022.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.